CN112725287A - Strong-lytic staphylococcus aureus phage RDP-SR-20001 and application thereof - Google Patents
Strong-lytic staphylococcus aureus phage RDP-SR-20001 and application thereof Download PDFInfo
- Publication number
- CN112725287A CN112725287A CN202110052915.7A CN202110052915A CN112725287A CN 112725287 A CN112725287 A CN 112725287A CN 202110052915 A CN202110052915 A CN 202110052915A CN 112725287 A CN112725287 A CN 112725287A
- Authority
- CN
- China
- Prior art keywords
- staphylococcus aureus
- bacteriophage
- rdp
- phage
- bacteriophage rdp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 75
- 241001515965 unidentified phage Species 0.000 claims abstract description 70
- 230000002101 lytic effect Effects 0.000 claims abstract description 10
- 238000009395 breeding Methods 0.000 claims abstract description 8
- 230000001488 breeding effect Effects 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 230000009089 cytolysis Effects 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000645 desinfectant Substances 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001018 virulence Effects 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 244000144977 poultry Species 0.000 abstract description 12
- 241000287828 Gallus gallus Species 0.000 abstract description 9
- 230000001717 pathogenic effect Effects 0.000 abstract description 9
- 239000010865 sewage Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 206010041925 Staphylococcal infections Diseases 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 208000015339 staphylococcus aureus infection Diseases 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607594 Vibrio alginolyticus Species 0.000 description 2
- 241000607618 Vibrio harveyi Species 0.000 description 2
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001320 lysogenic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000269335 Ambystoma laterale x Ambystoma jeffersonianum Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/40—Viruses, e.g. bacteriophages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/381—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Agronomy & Crop Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
The invention discloses a strong lytic staphylococcus aureus bacteriophage RDP-SR-20001 and application thereof in pathogenic staphylococcus aureus infection of poultry. The method comprises the steps of screening a staphylococcus aureus BS-20001 strain from diseased broiler tissues in Qingdao and Jimo broiler farms by a double-layer plate method, and then separating staphylococcus aureus bacteriophage RDP-SR-20001 from the sewage of the farms by using a staphylococcus aureus BS-20001 host, wherein the preservation number is CGMCC No. 21409. The pathogenic staphylococcus aureus BS-20001 in the poultry breeding environment of the staphylococcus aureus bacteriophage RDP-SR-20001 provided by the invention has strong lytic effect, and provides a bacteriophage source for the industrial production of the bacteriophage for preventing and treating the pathogenic staphylococcus aureus in the poultry breeding environment.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a strong lytic staphylococcus aureus bacteriophage RDP-SR-20001 and application thereof.
Background
Staphylococcus aureus (Staphylococcus aureus) is an important pathogenic bacterium in human beings, belongs to the genus Staphylococcus (Staphylococcus), is called as a "mesophilic bacterium", is a representative of gram-positive bacteria, and can cause many serious infections. Staphylococcus aureus is ubiquitous in nature and is found in air, water, dust and human and animal excreta. Thus, there are many opportunities for food to become contaminated therewith. Staphylococcus aureus is pathogenic to both animals and humans. Wherein air pollution is the major route of transmission in animal populations. Rabbits are sensitive to staphylococcus aureus and can cause rabbit septicemia when infected through skin surface lesions. Infection of mice with staphylococcus aureus can bow a skin soybean-sized spot or septicemia. Staphylococcus aureus infection of poultry such as broiler chicken can cause arthritis, tendonitis, septicemia, peritonitis, etc. Staphylococci always exist in places such as farms, hospitals and communities, and if the prevention and treatment are not good, large-area infection can be caused, so that not only is serious loss caused to the breeding industry, but also the life safety of human beings can be endangered.
The traditional treatment mode of staphylococcus aureus is antibiotic treatment, but along with the use and abuse of a large amount of antibiotics in the breeding industry, the drug resistance of staphylococcus aureus to antibiotics is gradually enhanced, so that the treatment of infection caused by the staphylococcus aureus is more and more difficult, especially in recent years, "super bacteria" capable of resisting methicillin is separated clinically, so that the prevention and treatment of staphylococcus aureus are more and more difficult, and therefore, a novel drug is urgently needed to replace antibiotics for treatment.
Bacteriophages (phages) are a generic term for viruses that infect microorganisms such as bacteria, fungi, algae, actinomycetes, or spirochetes, and are called phages because they partially cause lysis of host bacteria. The phage exists widely in nature, and corresponding phage may exist in places where bacteria grow. About 10 on earth is predicted31The phage has been classified and identified and reported to be close to 5100 phage. These abundant phage resources provide valuable materials for the development and utilization of phage.
Compared with antibiotics, the bacteriophage has the characteristics of strong specificity, difficult antibody generation, safety, no drug residue, strong proliferation and the like, and can safely, efficiently and quickly kill specific pathogenic bacteria. Therefore, screening and applying suitable phage is an effective way to prevent and treat staphylococcus aureus infection.
The invention provides a safe and reliable strong lytic staphylococcus aureus bacteriophage for treating staphylococcus aureus, which is used for solving the problems of bacterial drug resistance and antibiotic abuse in order of comprehensive banning of corresponding countries.
Disclosure of Invention
The invention aims to provide a strong lytic staphylococcus aureus bacteriophage RDP-SR-20001, and aims to solve the difficulties that poultry in a farm are not treated timely due to acute disease caused by infection of staphylococcus aureus and drug taking is ineffective due to drug resistance of pathogenic bacteria.
In order to achieve the purpose, the invention adopts the following technical scheme:
a strong lytic staphylococcus aureus bacteriophage RDP-SR-20001, which is observed by a transmission electron microscope, has a diameter of 1-2mm, is round and transparent, has no halo, has a head part with a regular polyhedron structure, a diameter of about 41nm, and no tail part, and is a capsphage family; the total length of the genome is 17085bp, and the genome has no virulence genes and lysogenic genes; the phage is preserved in China general microbiological culture Collection center (CGMCC) at 12 months and 17 days in 2020, and the preservation addresses are as follows: the number of the collection is CGMCC No.21409, No. 3 of Xilu No. 1 of Beijing Chaoyang district.
The bacteriophage is a virulent bacteriophage, has strong lytic property to pseudomonas aeruginosa, has a lysis rate of 95 percent, and provides a bacteriophage source for industrialized, large-scale and programmed production of the bacteriophage and treatment of poultry breeding animal bacterial diseases caused by staphylococcus aureus.
Further, the bacteriophage RDP-SR-20001 is treated at 50 ℃ for 1h, and the titer is still kept at 109pfu/ml or more.
Further, the bacteriophage RDP-SR-20001 is cultured at 37 deg.C for 60min at pH5.0-9.0, and the titer is still maintained at 1010pfu/mL or more, completely losing the ability to infect a host at pH 2.0; at pH 12.0, the titer of the phage remained at 103pfu/mL, phage RDP-SR-20001 has acid intolerance and alkalophilicity.
The bacteriophage can be used for industrial production, can be specifically amplified by host bacteria, and can be used as a biological disinfectant to be applied to poultry farms, animal husbandry, food, medicines, medical instrument factories, hospitals and other environment disinfectants for human activities.
The bacteriophage is added into poultry feed as a feed additive, has obvious inhibiting and killing effects on staphylococcus aureus in poultry bodies, and can effectively prevent the occurrence of poultry staphylococcus aureus.
The invention also provides a bactericidal composition for preventing and treating staphylococcus aureus, and the effective component of the bactericidal composition comprises staphylococcus aureus bacteriophage RDP-SR-20001.
The invention also provides a feed for preventing and/or treating diseases caused by pseudomonas aeruginosa, and the effective component of the feed comprises the staphylococcus aureus bacteriophage RDP-SR-20001.
The invention also provides a cleaning agent or a disinfectant, the effective component of which comprises the staphylococcus aureus bacteriophage RDP-SR-20001.
The invention has the beneficial effects that:
(1) the invention obtains a staphylococcus aureus BS-20001 from diseased broiler tissues of a Qingdao, i.e. Memo-broiler farm by screening, and obtains a staphylococcus aureus bacteriophage RDP-SR-20001 from the sewage of the farm by taking the staphylococcus aureus BS-20001 as a host through separation, wherein the bacteriophage RDP-SR-20001 has strong cracking effect on pathogenic staphylococcus aureus BS-20001 in a poultry breeding environment, and provides a bacteriophage source for industrial production of the bacteriophage for preventing and treating the pathogenic staphylococcus aureus BS-20001 in the poultry breeding environment;
(2) the staphylococcus aureus bacteriophage RDP-SR-20001 provided by the invention can maintain better activity in the range of pH5.0-9.0, the bacteriophage titer is not obviously changed, and the bacteriophage titer is highest when the pH is 9.0; the titer of the phage is obviously reduced along with the reduction of the pH value, and the capability of infecting the host is completely lost when the pH value is 2.0; but has better stability in alkaline environment, and the titer of the phage is still kept at 10 when the pH is 12.03pfu/mL or so; has acid and alkalophilicity;
(3) the staphylococcus aureus bacteriophage RDP-SR-20001 can be used for industrial production and can be specifically amplified by host bacteria staphylococcus aureus BS-20001; the bacteriophage can also be used as a safe biological disinfectant for environmental disinfection and animal body surface disinfection, thereby treating animal farm pollution; the bacteriophage can also be used as a medicine for preventing and treating diseases caused by staphylococcus aureus.
Drawings
The above and other features, properties and advantages of the present invention will become more apparent from the following description of the embodiments with reference to the accompanying drawings:
FIG. 1 is a schematic diagram of the separation and purification of Staphylococcus aureus BS-20001 according to example 1 of the present invention;
FIG. 2 is a schematic representation of the phage plaques obtained in example 2 of the present invention.
FIG. 3 is an electron micrograph of Staphylococcus aureus bacteriophage RDP-SR-20001;
FIG. 4 is a graph of one step growth of Staphylococcus aureus bacteriophage RDP-SR-20001 of the present invention;
FIG. 5 is a schematic diagram of the acid-base tolerance test of Staphylococcus aureus bacteriophage RDP-SR-20001 according to the present invention;
FIG. 6 is a schematic diagram of the heat stability experiment of Staphylococcus aureus bacteriophage RDP-SR-20001 of the present invention;
Detailed Description
The invention is further illustrated by the following figures and examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
The staphylococcus aureus BS-20001 is obtained by screening diseased broiler tissues in a Qingdao, Yimo and broiler farm, pathogenicity and drug resistance of the BS-20001 are determined through experiments, and a staphylococcus aureus bacteriophage RDP-SR-20001 is obtained by separating sewage of the chicken farm by taking the BS-20001 as a host; and the genotype of RDP-SR-20001 is determined by the whole genome sequence.
Example 1 isolation and identification of pathogenic Staphylococcus aureus BS-20001
Sampling from a diseased farm, taking a joint exudate, a liver and a spleen of a diseased chicken through aseptic operation, streaking on a BHI culture medium, culturing at 37 ℃ for 24-48 h, carrying out gram staining and microscopic observation on bacteria growing on a plate, carrying out plate streaking purification on bacterial colonies with gram staining as positive cocci again, repeating the steps for 3 times until bacterial colonies with uniform size and shape are grown, then selecting a single bacterial colony to inoculate in 5mL LB broth, and carrying out shaking culture at 37 ℃ and 200rpm for 10h to obtain a uniform and turbid bacterial suspension. And determining the strain to be pathogenic staphylococcus aureus by biochemical identification and 16sRNA molecular identification, and storing one strain of the pathogenic staphylococcus aureus under the name of BS-20001 (shown in figure 1) in a refrigerator at the temperature of-80 ℃.
Example 2 isolation and characterization of Staphylococcus aureus phage RDP-SR-20001
(1) Sewage treatment: collecting sewage from a farm, primarily filtering the collected sewage sample by using a plurality of layers of gauze, then placing the filtrate at 4 ℃ for 10000 Xg centrifugation for 15min, filtering the supernatant by using a disposable filter with the pore diameter of 0.22 mu m, and placing the filtrate at 4 ℃ for later use;
(2) preparing a mixed bacterial suspension: 0.2mL of the bacterial suspension and 1mL of the filtrate were added to 5mL of LB broth, incubated overnight at 37 ℃ with shaking at 200rpm, and then centrifuged at 10000rpm for 5min, and the supernatant was filtered through a 0.22 μm filter to prepare a filtrate.
(3) Phage separation: separating phage by using a double-plate method, uniformly mixing 0.1mL of mixed bacteria suspension filtrate with 0.8978 mL of staphylococcus aureus BS-200010.2 mL, carrying out water bath at 37 ℃ for 10min, then paving double plates, putting the double plates in an incubator at 37 ℃ for culturing for 6-8h, and observing that transparent spots are formed on the plates; and (3) picking the transparent spots, fully and uniformly mixing the transparent spots in 1mL of SM buffer solution, standing the mixture at 4 ℃ for 6 hours, then diluting the phage soaking solution in a multiple ratio, and repeating the operation of the double-layer plate. This procedure was followed 3 times to obtain a phage, which was designated as RDP-SR-20001. As can be seen from FIG. 2, the plaques formed by the phage are uniform in shape and size, round and transparent, clear in edge, and about 1-2mm in diameter.
(4) The purified phage multiplication fluid was mixed with glycerol (30%) and stored in liquid nitrogen.
(5) Measuring the titer of the phage: centrifuging bacteriophage proliferation solution at 10000rpm for 5min, collecting supernatant, filtering with 0.22 μm filter to obtain filtrate, diluting the filtrate with SM buffer solution by 10 times, and diluting to 10 times8Taking 0.1mL of each of the diluent and the bacterial suspension of the last 3 dilutions, preparing a double-layer flat plate, inverting after condensation, and culturing at constant temperature of 37 ℃. Phage titer (pfu/mL) is plaque number × dilution multiple × 10; the result shows that the titer of the phage can reach 1011pfu/mL or more.
EXAMPLE 3 Electron microscopy of phages
The phage is treated by adopting a phosphotungstic acid negative staining method: dropping 100 μ L of purified and multiplied phage on a paraffin plate, placing the surface of a copper net with a membrane on a phage droplet, taking the copper net off the droplet after 10min, placing the copper net on clean filter paper, drying for 3min, adding a drop of 2% phosphotungstic acid (PTA) on the copper net to dye the phage for 10min, then sucking the dyeing solution from the side by using the filter paper, and observing the form of the phage by using an electron microscope after the sample is dried.
As can be seen from FIG. 3, the head of the bacteriophage RDP-SR-20001 is a regular polyhedron structure, the diameter is about 41nm, and no tail is present; according to the ninth report of the organization of viral taxonomy of International taxonomy of viruses, the form of the phage conforms to the characteristics of the Capsioviridae family.
Example 4 phage genome sequencing
After enrichment culture of a single phage, centrifuging for 15 minutes at 8000r/min at 4 ℃, adding 10% PEG8000 and 0.5M NaCl, standing overnight, adding equal amount of chloroform, mixing uniformly, standing for layering, centrifuging for 10 minutes at 5000r/min, removing a chloroform layer and a PEG layer, adding restriction endonuclease for digestion treatment, suspending the phage under the condition of gradient density cesium chloride, dialyzing for 3 times at the later stage by TM buffer solution, and performing whole genome sequencing by Chihuada gene biosequencing company for 30 minutes each time. Sequencing results show that the whole length of the phage genome is 17085bp, and the phage genome does not have virulence genes and lysogenic genes.
Example 5 optimal multiplicity of infection assay
Optimal multiplicity of infection (MOI) assay: 1 in terms of multiplicity of infection, respectively: 1. 1: 10. 10: 1. 100, and (2) a step of: 1. 1000: 1, adding the phage and BS-20001 into a nutrient broth culture medium, carrying out shaking culture at 37 ℃ for 10h, carrying out 12000 Xg centrifugation at 4 ℃ for 15min, filtering the supernatant by using a disposable filter with the pore diameter of 0.22 mu m, and measuring the titer of the phage at the moment, wherein the corresponding multiplicity of infection when the obtained phage titer is the highest is the optimal multiplicity of infection of the phage. The results are shown in Table 1.
TABLE 1 optimal multiplicity of infection for bacteriophage RDP-SR-20001
As can be seen from the data in Table 1, when the infection number is 1:100, the growth medium is relatively clear and the titer is the highest after 10 hours of culture, indicating that the optimal infection number of RDP-SR-20001 is 1: 100.
Example 6 determination of phage growth curves
Taking staphylococcus aureus BS-20001 in logarithmic growth phase, inoculating the staphylococcus aureus BS-20001 and phage RDP-SR-20001 according to the optimal complex number of infection, carrying out water bath for 10min at 37 ℃, then centrifuging for 5min at 12000r/min at normal temperature, removing supernatant, removing free phage not adsorbed on a host, and washing twice by using LB broth culture medium. The pellet was resuspended in LB broth at 37 ℃ and quickly placed on a shaker at 37 ℃ and 200r/min for shaking culture and timing. Sampling and counting every 5min for the first 30min, counting every 10min for 30-200min, drawing a growth curve by taking time as a horizontal coordinate and a bacteriophage titer logarithm value as a vertical coordinate, obtaining the incubation period and the lysis period of the bacteriophage, and calculating the average lysis amount. Wherein the average lysis amount is the phage titer at the end of outbreak/the host bacteria concentration at the initial stage of infection.
As can be seen from FIG. 4, the titer did not change significantly within 15min after the phage infected the host bacteria, indicating that the incubation period was about 15min, and the titer of the phage increased significantly within 20-90min after infection, then became stable, indicating that the phage lysis period was about 70 min. By calculation, the average lysis amount of the phage is 108, and the phage shows extremely strong lysis and replication capacity.
Example 7 acid-base resistance test
Adjusting pH of normal saline with dilute hydrochloric acid and dilute NaOH solution to obtain buffer solution with pH of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and diluting bacteriophage with SM buffer solution to 1 x 1010pfu/mL, the dilution was incubated at 37 ℃ for 1h in a water bath, diluted 10-fold with physiological saline and plated on double plates. Counting after inverted culture at 37 ℃ for 4-6 h.
Referring to FIG. 5, it can be seen that the phage RDP-SR-20001 maintained good activity at pH5.0-9.0 after cultivation under different pH conditions, the phage titer did not change significantly, and the phage titer was highest at pH 9.0. The titer of the phage decreased significantly with decreasing pH, and completely lost the ability to infect the host at pH 2.0. But has better stability in alkaline environment, and the titer of the phage is still kept at 10 when the pH is 12.03pfu/mL, which shows that the bacteriophage RDP-SR-20001 has acid and alkalophilicity; the phage grows optimally in a neutral environment.
Example 8 thermal stability experiment
The phage stock solution is subpackaged into EP tubes, incubated for 30min and 60min at 40 ℃, 50 ℃, 60 ℃, 70 ℃ and 80 ℃ respectively, then diluted by 10 times of SM buffer solution, and spread on a double plate to determine the titer.
As can be seen from FIG. 6, the activity of the phage remained stable within 30 ℃ to 50 ℃, the activity of the phage was reduced by about half at 60 ℃ and 70 ℃ and was substantially inactivated at 80 ℃ and higher temperatures. Therefore, the bacteriophage RDP-SR-20001 has poor high temperature tolerance and is suitable for living in the environment of 50 ℃ and below.
Example 9 cracking Rate experiments
Under the aseptic condition, respectively taking 1mL bacteriophage RDP-SR-20001 and 1mL host bacterium BS-20001 bacterial liquid, incubating for 15 minutes at 37 ℃, mixing uniformly, diluting with SM buffer solution to10-1-10-3Each gradient was plated at 100. mu.L onto a plate and incubated at 37 ℃ for 24 hours, with each gradient repeated twice. Simultaneously taking 1mL of SM buffer solution and 1mL of host bacterium BS-20001 bacterium solution as blank controls, and repeating the steps. Plates with 30-300 colonies were picked for enumeration. This test was repeated 3 times, and the average value was taken to calculate the phage lysis rate. The phage lysis rate was (1-number of treated colonies/number of control colonies) × 100%. Through calculation, the cracking rate of RDP-SR-20001 reaches 95%, and the microbial composite has a good cracking effect on a host and is suitable for being used in a culture process.
Example 10 fragmentation Spectrum experiments
30 staphylococcus (including 17 staphylococcus aureus, 7 staphylococcus epidermidis and 6 staphylococcus saprophyticus), 10 salmonella, 5 escherichia coli, 1 vibrio alginolyticus, 1 vibrio harveyi and 3 vibrio parahaemolyticus which are identified in a laboratory are selected to carry out a lysis spectrum experiment. The phages were reacted with different species of standard strains. As shown in table 2.
TABLE 2
As can be seen from Table 2, the bacteriophage RDP-SR-20001 can not crack Escherichia coli, Salmonella, Vibrio alginolyticus, Vibrio harveyi and Vibrio parahaemolyticus, but can crack staphylococcus, which shows that the bacteriophage RDP-SR-20001 has specificity only to staphylococcus. In 17 strains of staphylococcus aureus participating in detection, the phage can form plaques on plates of 15 strains of staphylococcus aureus, 3 strains of staphylococcus epidermidis and 4 strains of staphylococcus saprophyticus, so that the phage can crack 15 strains of staphylococcus aureus (chicken source, cattle source, pig source and duck source including one MRSA strain) and can crack staphylococcus saprophyticus and staphylococcus epidermidis and the like. This experiment shows that the bacteriophage RDP-SR-20001 has a broad host spectrum and can crack part of drug-resistant strains separated from meat products.
It should be noted that the specific embodiments are merely representative examples of the present invention, and it is obvious that the technical solution of the present invention is not limited to the above-mentioned examples, and many variations are possible. Those skilled in the art, having the benefit of this disclosure and the benefit of this written description, will appreciate that other embodiments can be devised which do not depart from the specific details disclosed herein.
Sequence listing
<110> Ray union (Qingdao) bioengineering Co., Ltd
<120> strong lytic staphylococcus aureus bacteriophage RDP-SR-20001 and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 17083
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 1
aaatagtata tgtgattttt ttatgtaaat ttacacctcc ccaccgatta aaataaacga 60
ttataaaatc aaaaacttat aaattaactt atcatttcta aactaaactt ataaatactg 120
tgcaacaact tttccaactt atccaaccta ttaaatattc ataaaataca aaatttatgt 180
atctattgac ttttatttaa aattatgatt tgaaaataaa atctaatttc ttctattaaa 240
tagtagtttt aaattattta aaatttttaa tgatactcta ttgacaaaat ttttaaacgt 300
ttgttatact gttaatgtaa tcaaatcaag gaggtaacaa aatggttaat gttgataatg 360
caccagaaga aaaaggacaa gcatatactg aaatgttaca actattcaat aagttgattc 420
aatggaatcc agcatataca tttgacaatg caatcaactt agtatccgct tgtcaacaac 480
tattattaaa ctataacagt tctgttgttc aattcttaaa tgatgaatta aacaacgaaa 540
ctaaaccaga atcaatattg tcttatattg ctggtgatga cgctattgaa cagtggaaca 600
tgcacaaagg attttatgaa acgtataatg tttacgtttt ttagaaagga gtgatataat 660
aatgaaacct gatgatattg ttacattaag aattaaggga tatattcttc attatttgga 720
tgataaaaat gaatatgttg aagaatttat cccacttcat gagtaccatt tatcaaaaac 780
acaagcaaaa gatttaatct cacaatcata tacactatta tccactacac gcacaacgaa 840
aacaattcaa gtttattaca atgacctact acaaattgca attgcagaaa gcaaataatt 900
taaataagag gagaaataaa aatgacaaac gtaaaagata ttttatcaag acaccaaaac 960
acattagcga gatttgaatt tgaggaaaaa gaaagagaat ttattaaact atcagaatta 1020
gtagaaaaat acggtatgaa aaaagagtat atcgttagag cattattcac aaacaaagaa 1080
tcaaaattcg gtgaacaagg tgttatcgtc actgacgact ataatgtaaa cttaccgaac 1140
cacttaacag agttaattaa agaaatgaga gcagacgagg acgttgttaa cattatcaat 1200
gctggtgaag ttcaattcac aatttatgag tatgaaaata aaaaaggtca aaaaggttac 1260
tcaatcaact ttggtcaagt atcattttaa tacaatttca taggggatat ttatccccta 1320
tttttatgag gtgctaaaca atggaaaaaa tatacactgc cgtattatta tacaatgtat 1380
caattaatga aacatatgaa catgaaattg aacaattcga aaaaataaat aaagttaagg 1440
taatatatag ttatttcgac gcaaattttt acaaaaaagg tgcatataat ctttgtgtaa 1500
aatacattaa ggagatataa aaatgatata tgattacgga ggatttaaag tccatgaata 1560
acccactaga tattattatt gttttccttt tagcattttt aattacactt gtaatactta 1620
tgacaatgca tatacgtgtg tcatttggtg ttttatttac tacattaatt atattctaca 1680
ttatcttttt agttgtcata tatggtttat atggaggtcg ttagcaatgg ttagacgtac 1740
gtcagcaatg gatagatggg taaaacaaaa agaagaaaga agaaaaaaag aagaagaaaa 1800
aaagaaaaaa gattttactg gagttgattt taagtttgac gatgttgatt tacaaaatgc 1860
ctatattgaa gcatgggaaa aatatagtta tttacctcat tttccaaaag ataaaaatgt 1920
aagttacgta ttagctaaat cattagttag tggaaaacat tcaaaacaat taaatcatat 1980
aattagtata tatgaacgta atgatgataa aaataacata aacgcaaatt ttcataaaaa 2040
cgcaatgatt aatattgaag cagaaaaaca tcaatcatca atatcgagat atataaaagg 2100
tataaatgat ttatttaata aaataggata taatgataga cctatgacaa caattgatga 2160
tgtaaaagtg aggtataatt ttttattcta tgccaaatac gataattaat tttaacactg 2220
taaacgacat aataaactat tacaaggaga aaaaacatgg tgaaacaaaa tcgtttagac 2280
atggtaagag attatcaaaa tgctgtcaat catgtaagaa aaaaaatacc agataactat 2340
aaccaaatag aattagtcaa tgaactcatg aatgatgata tagactatta catatctatt 2400
tcaaaccgtt ctgacggaaa atcgttcaac tatgtttcat tctttattta tttagctata 2460
aaacttgata ttaaatttac tttattatca cgtcattata cattacgtga cgcttaccgt 2520
gattttattg aggaaatcat tgacaaaaac ccactattca aatctaagcg tgtgactttt 2580
agaagtgcta gagattattt agctattatc tatcaagata aggaaatagg cgtgataaca 2640
gatttaaata gtgctactga tttaaaatat cattctaact ttttaaaaca ctaccctatt 2700
attatatatg atgagttttt agcacttgaa gatgactatt taattgatga gtgggataag 2760
ttaaaaacaa tttatgaatc aatcgaccgt aaccatggta atgttgatta tattggtttc 2820
cctaaaatgt tcttattagg taatgcggtc aacttttcaa gtcctatttt agccaattta 2880
aatatataca acttattaca aaaacataaa atgaatacat cacgacttta caaaaacatt 2940
tttttagaaa tgcgtagaaa cgattacgtt aatgaaaaac gtaatacacg agcgtttaat 3000
tcaaacgatg acgctatgac aactggtgaa ttcgatttta atgaatataa tttagcagat 3060
gataatttaa gaaatcatat caaccaaaac ggtgattttt tctatattaa aactgatgat 3120
aaatatataa aaattatgta taatgttgat acttttaatg ctaacatcat tgtaatacct 3180
tatacaaaac aatatgagtt ttgtactaaa atcaaagata ttgatgacaa tgttatttat 3240
ctaagagaag atatgtttta taaagaaaac atggaacgtt attactacaa tccaagtaat 3300
ttacattttg acaatgctta ttcaaaaaat tacgtggttg ataatgatag atatttatat 3360
ttagatatga ataaaattat aaaatttcat ataaaaaatg aaatgaagaa aaacatcaac 3420
gaatttgaaa gaaaagaaaa aatatatgaa gataactata tagaaaatac aaagaagtat 3480
ttaatgaaac aatacggctt ataaaaggtg tgttagatta tgggattact tgagtgtatg 3540
caatatcata aacatcaacg aaaaatgata ttgtattggg atattgaaac attatcatat 3600
aataaaataa acggacgcaa taaacctaca ctatataaaa acgtaacgta ttctgttgct 3660
attggttggt ttaatggtaa cgaaattgat gttgaagtat tccccagttt tgaagccttt 3720
tatgatgatt tttacaagta tgttaatcgc cgtgatacaa tcacaaaatc aaaaacaaat 3780
attatcatga ttgcacataa ctgtaataaa tacgataatc attttttact taaagacact 3840
atgcgttatt ttgataatat tacacgcgaa aatgtatatt tgaaatctgc agaagaaaat 3900
gaacatacaa taaaaattca agaagctact attttagcca aaaataaaaa tgtgatttta 3960
gaaaaacgcg ttaaatcttc aatcaattta gatttaacaa tgtttttaaa cggttttaaa 4020
tttaatatca ttgataactt tatgaaaacc aacacatcta ttgcaacatt aggtaagaaa 4080
ttacttgacg ggggttattt aacagaaaac caacttaaaa cagattttaa ttatacaatt 4140
tttgataaag ataacgatat gtcagatagt gaagcttatg actatgctgt taagtgtttt 4200
gataatctta catctgaaca attaacctac attcataatg acgtgataat attaggtatg 4260
tcccatattc attatagtga catttttcca aattttgact ataacaaatt aacattttca 4320
ctaaatatca tggaatctta cttgaataac gaaatgacgc gtttccaatt actcaatcaa 4380
tatggagata ttaaaatatc ttacacacat taccaattcc atgatatgaa tttttatgac 4440
tatatcaaat cgttttatcg tggtggtttg aatatgtata acaccaaata cataaacaaa 4500
ctaattgatg agccttgttt ttcaattgat attaattcga gttatcctta tgtgatgtat 4560
catgagaaaa ttccgacatg gttatacttt tacgaacact attcagaacc aacgttaata 4620
cctacttttt tagatgatga caattatttt tcattatata agattgataa atatgtattt 4680
aatcatgata tattgactaa aatcaaatca cgtgtattac gtcaaatgat tgtaaaatac 4740
tataataatg ataacgatta cgttaatatc aatacaaata cattaagaat gattcaagac 4800
attacgggta ttgattgcat gcatatacgt gttaattcgt ttgttatata tgaatgtgaa 4860
tactttcatg cacgtgatat tatttttcaa aattatttta ttaaaacaca aggtaagtta 4920
aaaaataaaa tcaatatgac atcaccttat gactatcata tcactaatga catcaacgaa 4980
cacccatact caaatgaaga ggttatgttg tcaaaagtag tactcaatgg tttatatggc 5040
atacctgcgt tacgttcaca ttttaattta tttcgtttag atgaaaataa cgaattgtat 5100
aacatcatta acggttataa aaacacagaa cgtaatattt tattttctac atttgtaaca 5160
tcacgttcat tgtataactt attagtacca ttccaatatt taacagaaag tgaaattgat 5220
gataatttta tttattgtga tactgatagt ttgtatatga aatccgttgt aaagccctta 5280
ttgaacccca gtttattcga ccctatatca ttaggcaaat gggatattga aaacgaacag 5340
atagataaga tgtttgtact caatcataaa aaatatgcat atgtaacaaa tggaaagatt 5400
aaaatagcct cagctggtat accgaaaaac gcctttgata caagcgtcga ttttgaaacc 5460
tttgtacgtg aacaattctt tgacggtgcc attattgaaa acaataaaag tatctataat 5520
gctcaaggta caatatcgat atatccgtct aaaactgaaa ttgtatgcgg taatgtatat 5580
gatgaatatt ttactgatga acttaatatg aaacgtgaat ttatcttaaa agacgctaga 5640
gaaaattttg accatagtca atttgatgat attctttata ttgaaagcga cattggttcg 5700
ttctcactta atgacttatt tccagttgta cgttcagtac ataataaatc aaatttaaat 5760
atattaaaaa atcaacatga tgacatcaaa aaggcaactg ttaaataaca gttgcctttt 5820
tcttttgaga taacatgaaa aatgtgtacg aaaattgatt atgttttgta ttttatttac 5880
tagcattact agcatgtatt tattatatca tagttaatta agcaatacca ctgaagaata 5940
caatattatc accagcgtta tgaggtacac cattaatgag tgtatacaat acaacccttg 6000
acggagcaac gtatggtgga acattatagt ttgctactaa gaatgaacca tcgtcaaaca 6060
cagcaacaac tacacccgtg tgaccgatac catatatgct tgcttgtaag tatggtggtt 6120
tacttgaaaa gccataaccg acagtagggt tgtgcgttgt tttagcgcct aactttttat 6180
aaacatacca cacacgttga ccgtttgtta tttgtccatc gtcggtaggt tgtcttttac 6240
catgtagttg tgacatatac gcccatgtta attctgtaca ttgtcctgca ttacccgttt 6300
gaggaaatat gttacctggt ttgtataaat attctttttt gaataaaggt acaccaattg 6360
cttttttata tttttctggt aactgtgcat acgtccagtt accaccaatg acacgaccac 6420
ttttaccatt tggtttgact gatttaccac taattggttt atggtctccg tcatcatcag 6480
tagggtttga actactaccc ccactatcta cttgcacgct atcaatcagt ttttttaatg 6540
aatcgagtag cccaatcgtc attttaatat gatatgtgtt gttaaatgtt ttttgtaatg 6600
taaaataatc attactaaaa aatttgtcac tacctatact gtgtacatcc cattgtaatg 6660
cgtcttgtac tttttttaat aattcttgca tggcttgttt tgctaaagcg agcagtgaac 6720
taccactgtc accactacta ccactgtcag acgaatcact aggtgaacca cctttaccgt 6780
ctaatttacc accccacgca agaatagtat tcgcaccgtc taaaaatgga ttaccatagt 6840
tttgtacttt attatatgac gctttcaaac ctaggggata atatgccgcc caagtagctg 6900
ctgctgttaa tggaatatac gcacgtccga ttgtacctgc tttcatattt ttagcaaaat 6960
ctgcattacc ttttctttgt acgtcttgag gtacaaagtg aacgatgtta cctgcgtcat 7020
accaagacgg ttgtcctgct tgttttgatt gtgatactaa ttttcttgca atgaatttag 7080
cgtctgttaa atagtcacct cgtgcagatg tatggttcaa ccaacctaaa ccagcgctat 7140
acccctcatt tttttcatat acagcaaaaa gagtaggcga cacacctatc tcttttactg 7200
cttttaatac ttgtctgatt ttactttcat taccaccaag ccatacatta aagcgtccat 7260
acccttttac tttagggact aactggtcta tcgttaaacc gaaatcatca ttaatatacg 7320
aatgcgtaaa tttatctatc ttctcttggt cgttcattat tatcactctt ttcagaatcg 7380
tttttaatta ctcttaattt atctttaatt tgttctggca ctaatacgtc catttctgca 7440
caattttcta cgatagataa gccctcattc gcaatataat agaaaatcgt aatcatgagt 7500
aagccacctt ttaattgtaa aatctggtca atgatgttcg ctaaaatgat aatacagaat 7560
atcaataatt ttttagcaaa acctttcatt gatttttttg accatagatt attattttta 7620
atggattttg aaatacctgt aataatatca acaaacatta atacaaataa aaaatatagt 7680
aattttaaat cgcctgcata tataaacatg tgaaacgctt ctgaatctgt aaacctaaat 7740
tttacttcat tcattttaca caccctctct aaatttgtta tttaatggat tttgtaacat 7800
agggttacct gaaccatcat tatgccaaaa tctcacacca gattctaaaa tagcttttaa 7860
ttgttccatt aacatagggt caatgtcacg tatggtatac gtaccagtac attttaaata 7920
gttgcaaaca gtcatactgt taatcggttc aataaatgaa ttatagtcat ttacttcaaa 7980
accaaataac atataatatt tttgtaagaa tgtaatttct ttgggagatg gaacactaat 8040
cttcatcgtt aaaccattaa tactatttgc aatttggaag gcgtttccca tttctgattc 8100
tgttactgat ggcggttgta atgctaaatc tttatattct gcttgttgtt gtttatagaa 8160
attatattct tcattaaact taccaaataa tgcagttgga cttaaattac ttgctacact 8220
tactgcgtca taaaaacgtg attttgggtc actaccattt aatacattat ctatacgact 8280
tgtgattaat tgactttctg cattacgctg tctattagct tgctgtgatt gacctaaaat 8340
accgttattg attaaaattg gtacttgtgc aaaactatta aatgttatat ttgtatttaa 8400
gaatgaacct gtatcaatta atatatcttt atttttagca agtatcggtc tatcgttttc 8460
agcactgtta taatcaactg gatatactcg cacttcatta tgataaccaa tgatggattt 8520
tgtacgtaac ttaacacctg ttttttgtga aattttacca gcgtcaagta acattgtgtt 8580
accgttccag tcataaaatt caatcgtcat gtactcatta cgtatcatat gtttaaactc 8640
gtctttttta gacaacatca tctcttgtag tttagtaaaa cttaatgata aatcgtttaa 8700
actccattct tttgattttc caccctgttt taatgtcttt aatccagtaa ttttttcact 8760
tgtcttaacg tcctctaaat cttttgtatt aataaaatct ttaggtaaca tttgaacctt 8820
ttgaaagttt tgtgtaatcc atggatatgc actcatttta tccataaagt taataaagtc 8880
accatattcc ataacgtata agttgactgg tgatgtgata ttgtcatata tcgtaccttt 8940
agacgtatct aagtttggct ctttttttgt accaaatttc tttgataaat cagcgcttga 9000
ctggaataac actaaatttt ccaaatactg ttgcatttgg ttatacacat agtttttatt 9060
agatactttt aacacatcat cattgttacg taacattggt aacatatagt tatacgtgcg 9120
ttttgataag tgttgacgtt caatattaac gtttgagagt tgctctaata cattaccttg 9180
cgtgtacgtc ataatagtat caatcacaaa atatatttta accactacat cattcacgta 9240
ttctatttga ttcacaaaag cgtaatagcg tctgtcctca aaatctgata aaaacgtcat 9300
atagttaatt ccttgtgcgt catgccactg catatctaca ttaatttcca ttctatcgcg 9360
tataaaatta tacggttgtt tggaatagtc taacgattta aaatgacgac catttaaaaa 9420
ataatcatca cgttcttgat tactattaaa atgaattgta ttttgataat ctgtaaacgg 9480
tgtgttatag aaaaacttaa aattcgttaa ttttctcata ttttcctcct aatataaaaa 9540
tagtcgtata aattatttat acgactatta tatcattttt attcaatgat ttgtgtatct 9600
ataacaaaac gtttatctcc atttgttaag tcactatctt gataagatga tgtaacaaaa 9660
tgtaattcgt tattaaagtt taaatacatt cttgtattta tcatttttgt atcaatggca 9720
cattgcgtat aatgatgtgt tgattttaaa tttgcattaa tactgcctaa ttttatatca 9780
ccatttttct tgattccttt aattacacct cttaattgaa tcgtgcgtat attattaatt 9840
gtaattatac gatattgcgg tgcaggataa ccactattac tatcacttgc aataatacca 9900
ctttctaatg taatatcttg ccaccctgta tcattcacag ttgttttatt ttcattaatt 9960
gtatttaaaa tttctatttt atcattagtt attgtagctg ttaaattgtt aatactttgg 10020
gtattattac ctacactttc ttttgtagag ataatatctt gtttattttt ttcaatatct 10080
gcttcatttt ttgtgttttt atcatctaat aaaagaattg cagattcatg attacttagt 10140
ttatttgtat gttctgattg aacatctgat aaatttttta tttttttatc ttgttgtaca 10200
ttatcttctt taatattaat aatgtctgta gcgttttgag aaatattatt tttatttgta 10260
gcgatatcat ttttattttt attaatgtct tttgtgttcg tattaatttt acttaataat 10320
tcatctttaa aggttaactt ataataatcc tcatcacgtc ttatataaat gttaccgtcc 10380
tttgtagtaa ttaagtcatt tgcttctact aaattatcat ttaatttata tacagagtca 10440
atgttgcgca aacttcttac aattctatca gccattgttt acacctctta tttatatcgt 10500
ttccaactaa attcaaagaa aaatcctaaa atacccatta tgagaacacc ccccaaggta 10560
caccaatact atatgcatta cctgtttttc cattccattg tctaactggt aaataataac 10620
gagttccttg ccagttataa ccaatccaaa ctaacccatc tgataaacaa acttcgtcat 10680
atggtgtata tccatttggt tggaaccaat atccattagg ttcacttaat ttaggactac 10740
ctacacgtgc aaatattggt aaaaatccac atgtaaatgt tgcattttca tttctgtaat 10800
atgttccgta ttggttttgt ttccaatttc caaatgtatt tacttttgat gtttctaata 10860
cattactatt actagcagaa aatttaggtc taataaagtg tgttacaccg tcataataat 10920
gtgttcttat tgttgctttt tcccaaccgt caaacccacc acctaaccag ttttgctcta 10980
aacatgtata ataatcaaga tttccacttg ttacacattg gatatgtcca tattgagaat 11040
ttgtgtatac tccaacatca cctaattgag gtttaaagct cggtgtattt tcatacaccg 11100
ttgctaaacc tttaaagtca ttattaattg cgtctttggc attaccccac atacgcactt 11160
taccgtcagt aatataatag atataagcga cagctaagtc catacattga aaaccatatg 11220
caccatcaaa gtcaacacca acaccttcat gtttatatat ccaatctttc gcttgttgtt 11280
gtgatttcat ttataacact cctatttttt atgttttgct acccattcat attcacgatg 11340
tttcgtatca ctgtttacat tactgaaaaa ctctttatat tctgatatat tagcctctaa 11400
tgtttgtctt acttcactaa ctgcgttacc acttgacaca cgtaaccatg caccaacacg 11460
ttttatttct tccggtgcgt ctttgaataa ttccatttgg ttacctgtaa tgtaatattc 11520
tccgggtgtt gtaacgtaag ctatccaatt attatattga cttgcttcta aatattcttg 11580
atattgtgcg tctgttttga ttgttgtcca taaaccataa tcccatttta atgtaaatac 11640
atcgagcgtc ataccacgca tgattttaac catttttcga ccagtagaaa aacgcgttaa 11700
ttcttgtact gtacctaatg tttgtgttgt agggtataca ttgatgaaac aaccagcgtc 11760
tataattttt ttactaccat tcattggcat atttttaagt ttactagctg taccaccgtc 11820
aatataatag aaccctgctt gtgttaagtc atttaaatcg tcaatatgat ctggaataga 11880
taacgcacga ccatcgtctt ttgttaattt atagttttgt gaacctctcg cacgtaatgc 11940
ttcaaagtgt tcatattctc caagttggaa gaaaccatat aaattattga atcgttttcc 12000
accgccgcca ttagtcatag caagtaataa cgatttacgc tttgttttag gattggtata 12060
aatacaaata ccctcaggct ctttaaagtt atcacgtggg aaattaattc cgtcttgata 12120
tgataattta aacggataat cataaatctt ttgacctgtt gttaatgaat atttaccgat 12180
ttgaacgtgt gaattaactg aactgttacc acttaaccag tataaatcat ctccgtcaac 12240
ggctatccct tgcatccaac gattatcatt gttttctgaa ttatcaatag tcatttcttt 12300
ttctacatta tcaatgtgat tttttacgtc agctcttgaa cgcacctgta ttgtcccgtc 12360
accgaatctt aaaacgattt tgtcatttgc ttcatcaatt aacggtgtaa acgtatgttt 12420
gtttaaaagt gactgtggtg tataatcggt taaccctttt gcttcttcta aatctaatac 12480
atagttatct ttataagcca cttgtaacag ttttgcaaca ccatcgtgat gtaaccatat 12540
tttcatttct ccattagatt gacgttctaa tccaattgtt gtaccatgac caccctgtac 12600
aatacgcata cttgaaatta agtcaccact aggcgttaat ttattaatcc aaaatccctc 12660
aggtgtttgt gagtcggatt gtgttgagta catttgatta gtttctttat caatattaat 12720
agattggttc acagcgttac gaataccgcc aaagcccatt acaaacttag gttcaagctc 12780
atttaattca aaaccattaa caaaacggtc aatgtcttta attaagtctt tcacttctgc 12840
tttaaaatca ttcatttgtt tcatttctgc aactttaaat aatgcaaatg cagatgtaag 12900
accagcacta tatttagtaa attcatcatg aataatttta tctattgtac cgtcatttaa 12960
ccaacctcta aataagtctt tagcttgttc tgggaatgct ttcattaatt catcccagtt 13020
tctgaaacgt ttttttaact catcgtcata gtcccaaata cgatgtgcta atacttcaat 13080
gagctttgat aatcttgaaa tataatcata atatgatttt gaattggtat tataatctgc 13140
tctatcatcg taaaacggtg tataacgttc tctcgtttta tatatttcgt ctaagaatgg 13200
acgaatgtca tcaaaatatt taaaatcgtt ttcattatat gccattattt aaccacctct 13260
accaaatttg taaaaaacat tttttatcaa attcatttaa aattttcttt cttaaatcgt 13320
atactttatc aatattatca attaaatact gttttgaaaa ttgtgtacct ttcgcattac 13380
ctttttgatt ttgattacgt tttgcgtttt gattactttc gttacttgat ttattcacag 13440
ttttaccgtt atcaatcgtg ttattgtcag caaattgtaa cgttgtttta tcaacatcaa 13500
tgttaacttc gctttgtggt aatgacgcat aagcatttct gtttgctgtc ataccagttg 13560
aattgtctaa agatgttgta ttttgatttg aagtttcgtc agtgttgctt gttgtatctt 13620
cgttatgttc tgtgaagcct tgcgattgta gatatttttc tacttcactt gatgaataaa 13680
ccacatttaa ataatcctca tgtgtgatac atacagtaat aacttgcata ccaaacgctt 13740
caactgtttg tctgttgatt tctctatcta aaaagtgtat tgtaaatgat tttttgaaaa 13800
gtaagtcaga taactcatct ttaagtttaa aacctttaaa cactttttca ttaatgattg 13860
ataaaacgtc tttgtcaaac ttcaacattt tttgcatgaa ttgaaattca tcatcataaa 13920
acgttaattt atcattattt acaaattcat taaaaccttt tttaattaat tctgatttaa 13980
taaaatcaaa taaagtcatt gtatatctag ccattgtatt cactactttc atcattagac 14040
aatgtatcta tcattgtgat ttctgaagta acttcatcgt cgtaatacgg tttaatatct 14100
aaaccataac gttttgataa gaatgtaatc ggttcacgac cttttaaata aatattacta 14160
tttgatgtgg taaaacctcg gttgcttttt gcctcttcgt cagatacacc actttcttta 14220
tcaacagcta aagagttaat acctaaatag ttacttaatt cactaatttt attttggtat 14280
tctcttttca tctcagttag tgctggaatc acactattac tggttaaatc tatgatatca 14340
tcatcggcgt taaacatagg tgacatttta acaaatggtg caccgttgta tatttccgat 14400
acaagttgat taactgactc atcattaatg tctgatttaa atattttgct aaattttgct 14460
tgcataatta atgaaaatcg agataaaaca acctcagata attcatcagt ataatgttct 14520
ataatttcta tatcactatt atattgaatt ggtttatttt gcatgacaac aaagttgcca 14580
ctcatacagt tatcatatat tttatgaatc tgtaagcatt catctggtat taaatagtct 14640
gggacaatga aataaatatc atcttttgtt aatcgttttt gaaattggaa gttaaagttt 14700
gatgaaaaat ttggtgcttg attaaagtaa gtattattta cgtaaccaag aatcataatt 14760
tgttcatttc ttgctttgcc aaccactaca ttgatgtttt gtcttaatgc tgattctaat 14820
tgaataaaat ctataccaac cgtatcacga ttggtatagt tgatgagtag tggtaaaaat 14880
tccaaataac gattaaacat aagacgttta aatctgttgc gatgttcaac aactcttttg 14940
ttgatttctt ttgataattc aacgtttaaa cctcttttat cgttgttcat atttacgctc 15000
cttttattct gttgcttctt cctctggttt tggtgttaca tcttggtcag taattaatat 15060
tttattaaag aatggactaa tagccttgaa tgaataataa tgaatccagt gtgtgacctc 15120
atcaaattca ccattataga atggttgttt taacatacct ttggtataac gtttgtattt 15180
aattgcatta atatctaaaa taaatgcata taaatctgat tttggtttaa tttcttcaat 15240
gttaccagta aactctttaa gtttagaaac atcataagta aatactgcac caactggaat 15300
tgtgtcaccc atttgcgact gataatcacc gtaagcacgt aaaaagttaa tagattcttg 15360
gttttgtaac ttaaattctt ttgttacttt aaacacacca cctaaatcgt caaaactgat 15420
aacgtggtct gtgaagtcaa taccagcaac ttggaacgta ttcgcaattt ttgtatctaa 15480
aagataagat tttaaagagt cagtcgttaa aataacaata tcttttaatt ttgatacagt 15540
tgtatattgt ccaattgcac caccagaagc acgatgaact tcattgtatt tagcgctgtt 15600
gttttgtaag tttaaaattg cttcaaatac tttgcttgct aaatcttctt tagatgttgt 15660
tttacgtaca tttgtatcag ataattgatt caatgaataa tcaactaaca ttgcacgcat 15720
ttctttttct tctaatacat taatatcaga aattttcttt ttatatacac ctaaagcata 15780
attagttgcg tctgctaatg tttggaaatt gaaacgtgta tcattattgt ttaatgtgaa 15840
tttttgtttc ttaacaatac cactaccata taacttagta gccatacgtg gatagttacg 15900
ttttaacatt aactcttcgt ttttagataa atccatgttg attggaacag tatccataat 15960
cacatattct tcactatatt gaccaataaa gtcttgttct ttagctaacc aattaaaacg 16020
attacctaaa gcgatatcga ttaataaagt ctcattaatc ttagggaata aatatttatt 16080
tacaaatgtt tcaaacattg tatttgaatt atcccatttg tctccaaatg tccaagattt 16140
tgaataatca tgattaaaat cttgcaatgc tgattttgcg gattttgcaa ctaaaagggc 16200
agtttcattt ttagtactcg cttgtgccat aatttattat tcctcctcta cgtctccgct 16260
aaaagactgt tttgaaagtg agtgaatttg tacaccgtac tcatcctcac ttttatttac 16320
atcgattgac atattttcat ttaattctgt tcgtttgttt aatcttgaat cttcatatga 16380
tgttcccatc atagaacgca tgttgttacc ttcatacata atattttcct cctaatctaa 16440
atctaacttg tcaactaatt cttcatctga atagtctttg tcttctttgt ctgcgtttgt 16500
tacatctggt tgtgtttgtt gtggttgttg aatttgtgat gaaacaaaag tagtcatttg 16560
ttgctctaat gatgtaatac gttgttctaa tacaacaggg tcgtattttg aactatcttc 16620
atctgttata gtaggttcta atttattctc attttctact tcaattgttt ctactgtttt 16680
atcttcagta ggttcttcag ttggttcttc agttagttct tcagttggtt cttcagttgg 16740
ttcttcagtt ttttcattgt cgtctggttt tacgatttca tcaaattctg tcattgtgac 16800
acctccaaaa tattttataa ctaattatat catagaatat ttaaataagt aaattaaatt 16860
tatttaaaag cgtgaacata gttttgaata aaagtcaata gatacataaa ttttgtattt 16920
gatgaatatt taataggttg gataagttgg aaaagttgtt gcacagtatt tataagttta 16980
gtttagaaat gataagttaa tttataagtt tttgatttta taatcgttta ttttaatcgg 17040
tggggaggtg taaatttaca taaaaaaatc acatatacta ttt 17083
Claims (10)
1. A strong lytic staphylococcus aureus bacteriophage RDP-SR-20001 is characterized in that the bacteriophage plaque has the diameter of 1-2mm, is round and transparent and has no halo when being observed through an electron microscope, the head of the bacteriophage plaque is of a regular polyhedron structure, the diameter of the head is about 41nm, the tail of the bacteriophage is not, and the bacteriophage is of Capricoraceae; the total length of the genome is 17085bp, and the genome has no virulence gene and lysogen gene and has a preservation number of CGMCC No. 21409.
2. The staphylococcus aureus bacteriophage RDP-SR-20001 according to claim 1, wherein the bacteriophage is a virulent bacteriophage, which has strong lytic activity against pseudomonas aeruginosa, and the lysis rate is up to 95%, thereby providing a bacteriophage source for industrialized, large-scale, programmed production of bacteriophage and treatment of avian breeding animal bacterial diseases caused by staphylococcus aureus.
3. Staphylococcus aureus bacteriophage RDP-SR-20001 as in claim 1, wherein the bacteriophage RDP-SR-20001 has a potency of 10 after 1h treatment at 50 ℃9pfu/ml or more.
4. Staphylococcus aureus bacteriophage RDP-SR-20001 as claimed in claim 1, wherein the bacteriophage RDP-SR-20001 is cultured at 37 ℃ for 60min at pH ranging from 5.0 to 9.0 and the titer is still maintained at 1010pfu/mL or more, completely losing the ability to infect a host at pH 2.0; at pH 12.0, the titer of the phage remained at 103pfu/mL, phage RDP-SR-20001 has a pH value of alkalophilicity.
5. Use of the staphylococcus aureus bacteriophage RDP-SR-20001 according to claim 1 in the manufacture of a medicament for the prevention and or treatment of a disease caused by staphylococcus aureus.
6. Use of the staphylococcus aureus bacteriophage RDP-SR-20001 according to claim 1 for the preparation of a food additive for the prevention and or treatment of diseases caused by staphylococcus aureus.
7. Use of the staphylococcus aureus bacteriophage RDP-SR-20001 according to claim 1 for preparing a feed for preventing and or treating diseases caused by staphylococcus aureus.
8. The effective component of the bactericidal composition for preventing and treating staphylococcus aureus comprises staphylococcus aureus bacteriophage RDP-SR-20001.
9. The active ingredient of the feed for preventing and/or treating diseases caused by pseudomonas aeruginosa comprises the staphylococcus aureus bacteriophage RDP-SR-20001.
10. A detergent or disinfectant, the active ingredient of which comprises Staphylococcus aureus bacteriophage RDP-SR-20001 as set forth in claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110052915.7A CN112725287B (en) | 2021-01-15 | 2021-01-15 | Strong-lytic staphylococcus aureus phage RDP-SR-20001 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110052915.7A CN112725287B (en) | 2021-01-15 | 2021-01-15 | Strong-lytic staphylococcus aureus phage RDP-SR-20001 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112725287A true CN112725287A (en) | 2021-04-30 |
CN112725287B CN112725287B (en) | 2022-03-22 |
Family
ID=75593286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110052915.7A Active CN112725287B (en) | 2021-01-15 | 2021-01-15 | Strong-lytic staphylococcus aureus phage RDP-SR-20001 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112725287B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112301001A (en) * | 2020-11-03 | 2021-02-02 | 华中农业大学 | Staphylococcus aureus phage LSA2311 and application thereof |
CN113621584A (en) * | 2021-08-23 | 2021-11-09 | 山东农业大学 | Staphylococcus aureus bacteriophage and antibacterial application thereof |
CN114231500A (en) * | 2021-12-15 | 2022-03-25 | 华中农业大学 | Mutant staphylococcus aureus bacteriophage and application thereof |
CN115261334A (en) * | 2021-07-02 | 2022-11-01 | 青岛诺安百特生物技术有限公司 | Staphylococcus phage, phage preparation and application thereof in preventing and treating staphylococcus infection diseases |
CN115418355A (en) * | 2022-10-08 | 2022-12-02 | 青岛市畜牧工作站(青岛市畜牧兽医研究所) | Staphylococcus lentus phage and separation method and application thereof |
EP4344399A4 (en) * | 2022-08-11 | 2024-04-03 | Phagelab Chile SPA | Bacteriophages and compositions thereof for controlling the growth of pseudomonas lundensis in meat products |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104845942A (en) * | 2015-04-22 | 2015-08-19 | 上海交通大学 | Bacteriophage able to split multiple resistant staphylococcus aureus, separation method and application thereof |
WO2015188230A1 (en) * | 2014-06-11 | 2015-12-17 | Stock And Animal Products Pty Ltd | Bacteriophage production method |
CN109082414A (en) * | 2018-06-29 | 2018-12-25 | 浙江工业大学 | A kind of staphylococcus aureus bacteriophage and application |
CN109251898A (en) * | 2018-09-25 | 2019-01-22 | 吉林大学 | One plant of staphylococcus aureus bacteriophage and application thereof |
-
2021
- 2021-01-15 CN CN202110052915.7A patent/CN112725287B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015188230A1 (en) * | 2014-06-11 | 2015-12-17 | Stock And Animal Products Pty Ltd | Bacteriophage production method |
CN104845942A (en) * | 2015-04-22 | 2015-08-19 | 上海交通大学 | Bacteriophage able to split multiple resistant staphylococcus aureus, separation method and application thereof |
CN109082414A (en) * | 2018-06-29 | 2018-12-25 | 浙江工业大学 | A kind of staphylococcus aureus bacteriophage and application |
CN109251898A (en) * | 2018-09-25 | 2019-01-22 | 吉林大学 | One plant of staphylococcus aureus bacteriophage and application thereof |
Non-Patent Citations (2)
Title |
---|
HANNA M OKSANEN等: "ICTV Virus Taxonomy Profile: Corticoviridae", 《J GEN VIROL》 * |
冯烨等: "噬菌体最新分类与命名", 《中国兽医学报》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112301001A (en) * | 2020-11-03 | 2021-02-02 | 华中农业大学 | Staphylococcus aureus phage LSA2311 and application thereof |
CN112301001B (en) * | 2020-11-03 | 2022-10-14 | 华中农业大学 | Staphylococcus aureus phage LSA2311 and application thereof |
CN115261334A (en) * | 2021-07-02 | 2022-11-01 | 青岛诺安百特生物技术有限公司 | Staphylococcus phage, phage preparation and application thereof in preventing and treating staphylococcus infection diseases |
CN115261334B (en) * | 2021-07-02 | 2023-06-27 | 青岛诺安百特生物技术有限公司 | Staphylococcus bacteriophage, bacteriophage preparation and application of bacteriophage preparation in preventing and treating diseases caused by staphylococcus infection |
CN113621584A (en) * | 2021-08-23 | 2021-11-09 | 山东农业大学 | Staphylococcus aureus bacteriophage and antibacterial application thereof |
CN113621584B (en) * | 2021-08-23 | 2023-03-14 | 山东农业大学 | Staphylococcus aureus bacteriophage and antibacterial application thereof |
CN114231500A (en) * | 2021-12-15 | 2022-03-25 | 华中农业大学 | Mutant staphylococcus aureus bacteriophage and application thereof |
CN114231500B (en) * | 2021-12-15 | 2023-09-12 | 华中农业大学 | Mutant staphylococcus aureus phage and application thereof |
EP4344399A4 (en) * | 2022-08-11 | 2024-04-03 | Phagelab Chile SPA | Bacteriophages and compositions thereof for controlling the growth of pseudomonas lundensis in meat products |
CN115418355A (en) * | 2022-10-08 | 2022-12-02 | 青岛市畜牧工作站(青岛市畜牧兽医研究所) | Staphylococcus lentus phage and separation method and application thereof |
CN115418355B (en) * | 2022-10-08 | 2024-03-26 | 青岛市畜牧工作站(青岛市畜牧兽医研究所) | Staphylococcus lentus phage and separation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112725287B (en) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112725287B (en) | Strong-lytic staphylococcus aureus phage RDP-SR-20001 and application thereof | |
KR101649849B1 (en) | Novel Clostridium perfringens bacteriophage Clo-PEP-1 and its use for preventing proliferation of Clostridium perfringens | |
CN112195158B (en) | Vibrio parahaemolyticus bacteriophage RDP-VP-19003 and application thereof | |
CN105176932A (en) | Method for prevention and treatment of escherichia coli infections using a bacteriophage with broad antibacterial spectrum against escherichia coli | |
CN113621584B (en) | Staphylococcus aureus bacteriophage and antibacterial application thereof | |
CN112760296B (en) | Vibrio parahaemolyticus bacteriophage RDP-VP-19010 and application thereof | |
CN113430173B (en) | Wide-cracking-spectrum high-temperature-resistant salmonella bacteriophage and application thereof | |
CN113583973B (en) | High-lytic Klebsiella pneumoniae RDP-KP-20007 and application thereof | |
CN113583971B (en) | Salmonella bacteriophage capable of simultaneously cracking escherichia coli and application thereof | |
CN113583966B (en) | Salmonella furciosus bacteriophage and application thereof | |
Chen et al. | Isolation and genomic characterization of PA-5, a novel virulent bacteriophage against Enterobacter hormaechei | |
KR20180042748A (en) | Novel Staphylococcus specific bacteriophage SA7 and antibacterial composition comprising the same | |
KR102341100B1 (en) | Novel Salmonella specific bacteriophage SS1 and antibacterial composition comprising the same | |
Han et al. | Isolation and Characterization of a Virulent Bacteriophage φPA-HF17 of Pseudomonas aeruginosa | |
CN115927205A (en) | Cross-species schizolysis type Klebsiella pneumoniae phage and application thereof | |
CN113583974A (en) | Lytic vibrio parahaemolyticus phage RDP-VP-21007 and application thereof | |
CN113913391A (en) | Cross-species cleavable Escherichia coli bacteriophage RDP-EC-20128 and application thereof | |
KR102193495B1 (en) | Novel Acinetobacter baumannii specific bacteriophage AB63 and antibacterial composition comprising the same | |
Jiang et al. | Characterization of the lytic phage flora with a broad host range against multidrug-resistant Escherichia coli and evaluation of its efficacy against E. coli biofilm formation | |
CN112646785B (en) | High-temperature-resistant virulent proteobacterium bacteriophage RDP-SA-20018 and application thereof | |
CN113046328B (en) | Stellera suppurative phage and medical application thereof | |
CN113528470B (en) | T4SS targeted phage vB _ EcoM _ X4 and application thereof | |
CN114574450B (en) | Ultraviolet-resistant Proteus mirabilis bacteriophage with broad cleavage spectrum, composition and kit thereof, and application of phage | |
Kim et al. | Genomic and phenotypic characterization of a lytic bacteriophage CF1 infecting the multi-drug resistant bacterium Citrobacter freundii | |
CN112111464B (en) | Escherichia coli phage DY1 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |